Neurology

Epilepsy Surgery in India and UAE | Complete Patient Guide

Q: What is the cost of epilepsy surgery in India versus the UAE?

The total cost of epilepsy surgery — encompassing the multi-day pre-surgical evaluation (video-EEG monitoring, FDG-PET-CT, neuropsychological testing, and invasive SEEG phase if required), the operative procedure, ICU and hospital ward stay, and post-operative outpatient follow-up — ranges from approximately $8,000 to $25,000 USD in India. This range reflects differences in the type of surgery performed: a straightforward temporal lobectomy with standard pre-surgical workup typically falls in the $8,000–$14,000 range, while cases requiring invasive phase II SEEG monitoring followed by open resection or neuromodulation device implantation (VNS, RNS, or ANT-DBS) approach the $18,000–$25,000 range. In the UAE (Dubai and Abu Dhabi), the equivalent packages range from $20,000 to $55,000 USD, reflecting higher facility and physician fees and a premium hospital environment at JCI- and DHA-accredited institutions such as Cleveland Clinic Abu Dhabi and Mediclinic City Hospital. Both destinations offer a saving of 50–80% compared to equivalent care in the United States, where total epilepsy surgery costs routinely exceed $100,000–$200,000 USD. GAF Healthcare provides itemized, transparent cost estimates for your specific case after a remote clinical review — contact our neurology team to receive a personalized quote.

Q: How long do I need to stay in the country before I am fit to fly home after epilepsy surgery?

The total required in-country stay for epilepsy surgery is typically 6–10 weeks, and patients should plan travel accordingly before booking flights. This extended timeline is driven by the multi-phase nature of epilepsy surgery: the pre-surgical evaluation phase alone — including epilepsy monitoring unit (EMU) admission for prolonged video-EEG, FDG-PET-CT, neuropsychological testing, fMRI, and any invasive SEEG phase II monitoring — typically occupies 10–21 days before the operative date is even set. The surgical procedure itself requires 5–10 days of in-hospital recovery (including ICU stay). Following hospital discharge, a mandatory post-operative outpatient period of 3–6 weeks is required before neurosurgical clearance for international air travel is granted. The fit-to-fly criteria include: complete wound healing, absence of post-operative seizure activity requiring urgent intervention, stable neurological status, resolution of any post-operative cerebral edema on imaging, and confirmed tolerance of resumed oral AED regimen. Long-haul flights carry additional risks post-craniotomy — including venous thromboembolism and changes in cabin pressure — that necessitate this waiting period. Patients who undergo minimally invasive procedures (laser ablation/LITT or neuromodulation device implantation only) may be cleared to fly in 4–6 weeks. GAF Healthcare's coordinators build your full itinerary around these clinical milestones to ensure you are not stranded or pressured to travel prematurely.

Q: What is the success rate of epilepsy surgery?

Success rates in epilepsy surgery are stratified by procedure type, underlying pathology, and the precision of pre-surgical EZ localization — and are best described using the validated Engel Classification system, where Engel Class I (worthwhile improvement; Class IA = completely seizure-free) is the benchmark outcome. For anterior temporal lobectomy (ATL) performed for mesial temporal lobe epilepsy with hippocampal sclerosis — the most common and best-studied indication — 60–80% of patients achieve Engel Class I seizure freedom at 2 years, with durable rates of 55–75% maintained at 5–10 years. Selective amygdalohippocampectomy achieves comparable seizure freedom rates (55–75%) in pure mesial temporal sclerosis cases. Lesionectomy for epilepsy-associated tumors (ganglioglioma, DNET) achieves Engel Class I in 70–80% of cases. Extratemporal resections (frontal, parietal, occipital lobe) yield seizure freedom in 40–60% of carefully selected patients. For neuromodulation (VNS, RNS, ANT-DBS), the benchmark metric shifts to responder rate (≥50% seizure reduction): approximately 50% of VNS patients achieve this threshold at 2 years; RNS achieves 55–65% responder rate at 6 years with a cumulative benefit curve that continues to improve over time; ANT-DBS achieves 56–69% median seizure reduction at 5 years. It is critical to understand that these outcomes are highly dependent on patient selection — which is why the comprehensive pre-surgical evaluation process at GAF Healthcare's partner centers is non-negotiable. The most important predictor of seizure freedom is complete resection of the epileptogenic zone with MRI-visible pathology in a non-eloquent cortex location.

Epilepsy surgery is a curative neurosurgical intervention designed to eliminate or significantly reduce seizure frequency in patients with medically refractory epilepsy — those who have failed two or more appropriately dosed antiepileptic drug (AED) regimens. Across leading epilepsy surgery programs, long-term seizure freedom rates range from 60% to 80% for well-selected candidates, with temporal lobe resection achieving the highest rates. GAF Healthcare connects international patients with JCI- and NABH-accredited centers in India and JCI- and DHA-accredited hospitals in the UAE, providing end-to-end care coordination, pre-surgical evaluation, and post-operative rehabilitation support at a fraction of Western costs.

Hospital Stay

7–10 days

Success Rate

70%

Available in

India

Epilepsy Surgery in India

Get Epilepsy Surgery at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.

Epilepsy Surgery in UAE

Epilepsy Surgery at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.

Overview

Hospital Stay: 5–10 days (varies by procedure: resective surgery vs. neuromodulation implant) • Total Stay in Country (Fit-to-Fly): 4–8 weeks (patients must be seizure-stable, wound-healed, and cleared by the neurosurgeon before international travel) • Success Rate: 60–80% seizure freedom (temporal lobe resection); 50–70% (extratemporal resection); 50–60% ≥50% seizure reduction (neuromodulation)

What Is It?

Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures arising from abnormal, excessive, or synchronous neuronal activity in the brain. Approximately 30–40% of all epilepsy patients develop drug-resistant epilepsy (DRE), defined by the International League Against Epilepsy (ILAE) as failure to achieve sustained seizure freedom despite adequate trials of two tolerated, appropriately chosen, and dosed AED schedules. DRE carries substantial morbidity: elevated risk of sudden unexpected death in epilepsy (SUDEP), cognitive decline, psychiatric comorbidities including depression and anxiety, progressive hippocampal sclerosis, and profound quality-of-life impairment. The physiological mechanism of seizure generation is a disrupted balance between excitatory glutamatergic and inhibitory GABAergic neurotransmission within a localized epileptogenic zone (EZ) — the cortical region indispensable for seizure generation whose complete removal or disconnection is necessary for seizure freedom.

The standard of care for DRE has evolved into a systematic pre-surgical evaluation protocol that maps the EZ with millimeter precision before any operative intervention. This workup integrates scalp video-EEG telemetry, high-resolution 3-Tesla MRI with dedicated epilepsy protocols (FLAIR, inversion recovery, T2-mapping), interictal and ictal SPECT (SISCOM), 18F-FDG PET-CT for hypometabolic zone identification, magnetoencephalography (MEG), functional MRI (fMRI) for eloquent cortex mapping, and — when non-invasive data are discordant — stereo-EEG (SEEG) or subdural grid implantation for invasive electrocorticography (ECoG). Neuropsychological assessment and intracarotid sodium amobarbital (Wada) test or fMRI-based language/memory lateralization complete the evaluation. Only after a multidisciplinary epilepsy surgery conference (MESC) reviews all data is a surgical candidacy decision made.

Surgical strategies range from resective procedures (temporal lobectomy, selective amygdalohippocampectomy, lesionectomy, multilobar resection, hemispherectomy/hemispherotomy) to disconnective approaches and implantable neuromodulation devices. The choice depends on EZ localization, proximity to eloquent cortex, underlying pathology (hippocampal sclerosis, focal cortical dysplasia, cavernous malformation, tumors, tuberous sclerosis), and patient risk tolerance. India's Tier-1 epilepsy centers — at institutions such as NIMHANS Bangalore, AIIMS New Delhi, Apollo Hospitals, and Kokilaben Dhirubhai Ambani Hospital — and UAE centers including Cleveland Clinic Abu Dhabi and Mediclinic City Hospital Dubai operate comprehensive epilepsy monitoring units (EMUs) that meet international benchmarks for this complex, multi-stage evaluation.

Candidates

• ELIGIBILITY CRITERIA:

• Confirmed diagnosis of drug-resistant epilepsy (failure of ≥2 appropriate AED regimens at adequate doses and duration per ILAE 2010 definition)

• Identifiable epileptogenic zone on pre-surgical evaluation (MRI-positive or MRI-negative with concordant functional imaging)

• Seizure semiology and EEG pattern consistent with a surgically resectable focus or a targetable neuromodulation candidate

• Acceptable surgical risk as determined by neurosurgical and anesthetic assessment

• Age: surgery is performed across all age groups, including infants and children with catastrophic epilepsies (Rasmussen encephalitis, hemispheric dysplasia)

• Patient/caregiver willingness to comply with post-operative AED tapering protocol and long-term neurological follow-up

• REQUIRED PRE-SURGICAL DIAGNOSTIC WORKUP:

• Prolonged scalp video-EEG monitoring (minimum 5–7 days in epilepsy monitoring unit to capture ≥3 habitual seizures)

• High-resolution 3-Tesla epilepsy-protocol MRI (FLAIR, T2, 3D-T1 volumetric, T2-mapping for subtle focal cortical dysplasia)

• 18F-FDG PET-CT (interictal hypometabolism mapping of EZ)

• Ictal SPECT and SISCOM (subtraction ictal SPECT co-registered to MRI) when available

• Neuropsychological battery (IQ, memory, language, executive function lateralization)

• fMRI for language and motor cortex lateralization (or Wada test if fMRI inconclusive)

• Magnetoencephalography (MEG) — particularly for MRI-negative cases

• Stereo-EEG (SEEG) or subdural grid implantation for invasive phase II monitoring when non-invasive data are discordant or EZ borders eloquent cortex

• Genetics panel (SCN1A, KCNQ2, CDKL5, MTOR-pathway mutations) especially in pediatric DRE

• Complete blood count, coagulation profile, metabolic panel, and cardiac evaluation (ECG, ECHO) pre-anesthesia

• CONTRAINDICATIONS / POOR CANDIDATE FEATURES:

• Generalized epilepsy syndrome with no focal EZ (e.g., idiopathic generalized epilepsy without a resectable focus)

• Bilateral independent seizure onsets without a dominant hemisphere focus that can be safely resected

• Epileptogenic zone overlapping primary motor, somatosensory, or language cortex where resection would produce unacceptable neurological deficit

• Significant active psychiatric illness (severe untreated psychosis, high suicide risk) that must be stabilized pre-operatively

• Medically unfit for general anesthesia (severe cardiopulmonary compromise)

• Patient/family refusal or inability to consent after thorough counseling on realistic outcomes and risks

• Progressive neurological disease as the underlying etiology (e.g., active autoimmune encephalitis requiring immunotherapy rather than surgery as primary treatment)

Procedure

RESECTIVE SURGERY (Curative Intent — Highest Seizure Freedom Rates):

1. Anterior Temporal Lobectomy (ATL) — Gold Standard for Temporal Lobe Epilepsy (TLE):

Removes the anterior 4–5 cm of the non-dominant temporal lobe (or 3–4 cm dominant side), including the hippocampus, amygdala, parahippocampal gyrus, and anterior temporal neocortex. Achieves Engel Class I (seizure freedom) in 60–80% of patients with mesial temporal sclerosis (MTS) at 2 years. Techniques include standard en-bloc resection or microsurgery-guided selective approaches.

2. Selective Amygdalohippocampectomy (SAH):

Limited resection targeting only the amygdala and hippocampus, preserving lateral temporal neocortex. Approaches include the transsylvian (Yasargil), transcortical, and subtemporal routes. Increasingly performed under intraoperative MRI (iMRI) guidance or neuronavigation to maximize completeness of hippocampal resection while minimizing neocortical disruption. Seizure freedom comparable to ATL in pure MTS; potentially superior neuropsychological profile.

3. Lesionectomy / Topectomy:

Precise removal of a discrete epileptogenic lesion — focal cortical dysplasia (FCD), cavernous malformation, low-grade epilepsy-associated tumor (LEAT: DNET, ganglioglioma), or cortical tuber. Performed with intraoperative ECoG to verify removal of surrounding epileptogenic cortex beyond the structural lesion. Neuronavigation, intraoperative ultrasound, and 5-ALA fluorescence (for tumoral lesions) enhance precision.

4. Multilobar Resection / Hemispherectomy / Hemispherotomy:

For patients with extensive unihemispheric epileptogenic pathology (Rasmussen encephalitis, large hemispheric dysplasia, Sturge-Weber syndrome, perinatal stroke). Hemispherotomy (functional hemispherectomy) uses white matter disconnection to achieve the equivalent of anatomical hemispherectomy with significantly reduced blood loss, surgical time, and risk of superficial cerebral hemosiderosis. Seizure freedom rates reach 60–70% in well-selected pediatric patients.

MINIMALLY INVASIVE & LASER-BASED APPROACHES:

5. MRI-Guided Laser Interstitial Thermal Therapy (MRgLITT / Laser Ablation):

A stereotactically placed laser fiber (1.6 mm diameter) delivers precisely titrated thermal energy (Visualase or NeuroBlate systems) to ablate the epileptogenic zone under real-time MRI thermometry. Particularly suited for mesial temporal structures, hypothalamic hamartomas, and periventricular nodular heterotopia. Eliminates open craniotomy; hospital stay 1–2 days. Seizure freedom rates for MTS: approximately 50–60% at 1 year (slightly lower than open resection but with dramatically reduced morbidity).

6. Stereoelectroencephalography (SEEG)-Guided Radiofrequency Thermocoagulation (RF-TC):

Using implanted SEEG electrodes already in place for diagnostic phase II monitoring, targeted radiofrequency thermocoagulation is applied to destroy a limited epileptogenic network. A palliative/minimally invasive option in patients with eloquent cortex involvement or those refusing open surgery.

NEUROMODULATION (For Non-Resectable Cases — Palliative, Significant Seizure Reduction):

7. Vagus Nerve Stimulation (VNS):

Implanted pulse generator (similar to pacemaker) stimulates the left vagus nerve at programmable intervals. FDA-approved adjunct therapy. Achieves ≥50% seizure reduction in ~50% of patients over 2 years; rare complete seizure freedom. Increasingly available with closed-loop, ictal-triggered autostimulation (AspireSR model).

8. Responsive Neurostimulation (RNS / NeuroPace):

Implanted cranial device with depth or subdural strip electrodes placed directly at the seizure focus. Continuously monitors EEG and delivers brief electrical stimulation upon seizure detection to abort ictal spread. Responder rate (≥50% seizure reduction) reaches 55–65% at 6 years with cumulative benefit over time. Optimal for bilateral temporal lobe epilepsy or seizure foci in eloquent cortex.

9. Deep Brain Stimulation (DBS) — Anterior Nucleus of Thalamus (ANT-DBS):

Bilateral high-frequency stimulation of the anterior nucleus of the thalamus (SANTE trial protocol). FDA-approved for DRE in adults ≥18 years. Median seizure reduction of 56–69% at 5 years. Particularly considered for patients with multifocal or generalized DRE not amenable to resection.

10. Corpus Callosotomy:

Surgical section of the corpus callosum (anterior two-thirds or complete) to prevent bilateral synchronization of seizure activity. Primary indication: atonic/drop attacks causing injury in patients with generalized DRE. Does not achieve seizure freedom but dramatically reduces injurious drop attacks in 50–75% of cases. Can be performed endoscopically (minimally invasive) at specialized centers.

INTRAOPERATIVE TECHNOLOGIES USED AT LEADING CENTERS:

• Neuronavigation (Stealth/Brainlab) with pre-operative MRI/PET/fMRI co-registration

• Intraoperative MRI (iMRI) for real-time resection completeness verification

• Intraoperative electrocorticography (ECoG) for margin confirmation

• Awake craniotomy with cortical stimulation mapping for eloquent cortex preservation

• Robotic-assisted SEEG implantation (ROSA Robot, Neuromate) for precision phase II electrode placement

• Intraoperative neurophysiological monitoring (IONM): somatosensory evoked potentials (SSEP), motor evoked potentials (MEP)

Cost of Epilepsy Surgery: India vs. UAE

The total cost of epilepsy surgery encompasses the multi-phase pre-surgical evaluation (EMU monitoring, PET-CT, neuropsychological testing, and often invasive SEEG), the operative procedure itself, ICU and ward stay, post-operative outpatient follow-up, and AED management. This makes it one of the more cost-intensive neurosurgical pathways — but international patients can realize savings of 50–70% compared to the United States (where all-inclusive costs can exceed $100,000–$200,000 USD) by seeking care in India or the UAE. India offers the lowest costs without compromising on tertiary neurosurgical expertise, while the UAE provides a premium hospital environment with world-class infrastructure and unparalleled accessibility for Middle Eastern, European, and African patients. Both destinations operate ILAE-aligned epilepsy programs with full neuromodulation and robotic SEEG capabilities.

Destination	Estimated Cost (USD)	Key Advantage
India	$8,000 – $25,000	~56% less than the UAE
UAE (Dubai/Abu Dhabi)	$20,000 – $55,000	Premium care, JCI/DHA accredited

Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.

Recovery & Aftercare

PHASE 1 — PRE-TRAVEL CONSULTATION (4–8 weeks before departure):

• Submit medical records, current MRI, EEG reports, and AED history to GAF Healthcare's neurology coordination team

• Remote review by destination epilepsy surgeon and neurologist; preliminary candidacy assessment communicated within 5–7 business days

• Receive a detailed treatment plan, itemized cost estimate, and medical visa invitation letter

• GAF Healthcare assists with Indian e-Medical Visa or UAE entry visa application

• Travel insurance briefing and fit-to-travel documentation arranged

PHASE 2 — ARRIVAL & PRE-SURGICAL EVALUATION (Days 1–14 at destination):

• Airport pickup by GAF Healthcare ground team; transfer to partner accommodation near the hospital

• Day 1–2: Admission to Epilepsy Monitoring Unit (EMU); baseline clinical assessment by epilepsy neurologist, review of prior workup

• Days 2–10: Prolonged video-EEG monitoring (AEDs gradually reduced under supervision to capture habitual seizures); concurrent MRI, FDG-PET-CT, neuropsychological testing, fMRI language mapping

• Days 10–12 (if required): Invasive phase II monitoring — robotic SEEG electrode implantation under general anesthesia; 3–5 days of intracranial EEG recording; electrodes removed bedside

• Day 12–14: Multidisciplinary Epilepsy Surgery Conference (MESC) — neurosurgeon, epileptologist, neuroradiologist, neuropsychologist present case; surgical plan finalized and communicated to patient/family with realistic outcome expectations

PHASE 3 — SURGICAL PROCEDURE (Day 14–16, approximately):

• Pre-operative: Anesthesia assessment, AED dosing optimization, bowel prep, IV access; patient and family counseling on intraoperative risks and post-op expectations

• Intraoperative (typical duration 3–6 hours for open resection; 2–3 hours for LITT/neuromodulation implant):

• General anesthesia (or awake craniotomy protocol for eloquent cortex cases)

• Scalp block, head fixation in Mayfield clamp, neuronavigation registration

• Craniotomy (or stereotactic frame placement for LITT/SEEG/DBS)

• Resection/ablation/device implantation with continuous IONM

• Intraoperative ECoG to confirm EZ removal (resective cases)

• Wound closure, hemostasis; transfer to neurosurgical ICU

• Post-operative Day 0–1: ICU monitoring (neuro checks q1h, ICP assessment, AED re-administration IV)

PHASE 4 — IN-HOSPITAL RECOVERY (Days 1–7 post-op):

• Day 1–2: Neurological status assessment; head CT to rule out hematoma; early mobilization with physiotherapist

• Day 2–3: Transfer to neurosurgical ward; oral AEDs resumed; wound care

• Day 3–5: Neuropsychological baseline reassessment; speech therapy if dominant hemisphere involved; occupational therapy

• Day 5–7: Surgical wound review; staple/suture removal planning; discharge planning initiated

• Day 7–10: Hospital discharge to partner accommodation (for outpatient follow-up)

PHASE 5 — POST-DISCHARGE OUTPATIENT RECOVERY (Weeks 2–6 at destination):

• Week 2: Outpatient wound review, suture/staple removal; seizure diary review; AED continuation at current doses

• Week 2–4: Activity restrictions: no driving, no swimming, no contact sports; light walking encouraged

• Week 3–4: Follow-up EEG; neurologist assessment of seizure outcome (Engel classification); cognitive function review

• Week 4–6: Neurosurgeon clearance for international travel; post-op MRI (3-month MRI scheduled remotely); AED tapering plan initiated (typically not before 1–2 years of seizure freedom)

• GAF Healthcare coordinates discharge summary, imaging CDs, AED prescriptions, and remote follow-up appointments before departure

PHASE 6 — HOME COUNTRY FOLLOW-UP (Months 1–24):

• Monthly telemedicine follow-up via GAF Healthcare platform with treating epileptologist for first 6 months

• AED dose optimization; formal AED tapering considered after 2 years seizure-free (individualized decision)

• 3-month and 12-month post-operative MRI review

• Driving restrictions lifted per local national guidelines (typically 6–12 months seizure-free)

• Long-term Engel Class outcome documentation at 1, 2, and 5 years

Risks & Considerations

Epilepsy surgery carries procedure-specific risks that vary substantially by the type and location of surgery, and patients must receive thorough informed consent through a multidisciplinary discussion. For temporal lobe resection, the most clinically significant risks include a 25–50% risk of verbal memory decline (dominant hemisphere ATL) and a 50–75% superior quadrantanopia (upper visual field loss) due to Meyer's loop involvement — typically not disabling but present. Dominant hemisphere surgery carries a 1–2% risk of language deficit (aphasia), substantially mitigated by awake craniotomy and intraoperative mapping. Surgical mortality for elective epilepsy resection at experienced centers is <0.5%. General surgical risks include wound infection (1–3%), CSF leak (1–2%), epidural or subdural hematoma (<1%), venous sinus injury, and anesthetic complications. For extratemporal surgery near primary motor or sensory cortex, contralateral weakness (hemiparesis) is a risk proportional to the proximity of resection to the central sulcus; intraoperative neurophysiological monitoring (IONM) reduces but does not eliminate this risk. Hemispherectomy/hemispherotomy carries higher blood loss risk and, in anatomical hemispherectomy (now largely replaced by hemispherotomy), a historical risk of superficial cerebral hemosiderosis. Neuromodulation devices (VNS, RNS, DBS) carry device-specific risks: VNS is associated with hoarseness (30%), cough, and dyspnea with stimulation, and rare left vocal cord paralysis (<1%); RNS and DBS implantation carry a 1–2% intracranial hemorrhage risk per electrode trajectory. Post-operative psychiatric changes — including transient depression or, rarely, de novo psychosis — occur in 5–10% of patients and must be anticipated and managed. Patients with pre-existing psychiatric comorbidities should have these stabilized before surgery. All candidates should understand that seizure freedom is not guaranteed; approximately 20–40% of patients continue to have seizures post-resection (though often at reduced frequency), and long-term AED continuation is typically required for at least 2 years even in seizure-free patients. The decision to pursue surgery must always be weighed against the ongoing risks of untreated DRE, including SUDEP risk of 1:100–1:1000 patient-years.

New Delhi, India

NABH NABL

Top Doctors for Epilepsy Surgery

Why Plan Your Treatment Through Gaf Healthcare?

GAF Healthcare provides comprehensive non-medical coordination throughout the entire epilepsy surgery journey, removing logistical barriers for international patients.

VISA & DOCUMENTATION — INDIA: GAF Healthcare issues a formal medical invitation letter from the treating hospital, enabling patients to apply for the Indian e-Medical Visa (e-MV), which permits a 60-day stay extendable up to 180 days — critical given the multi-week pre-surgical EMU monitoring phase. Visa applications are typically approved within 3–5 business days. We assist with documentation for up to two medical attendants (e-Medical Attendant Visa) traveling with the patient. For patients already in India who need to extend their stay for post-operative recovery, our team coordinates FRRO registration and extension applications.

VISA & DOCUMENTATION — UAE: Patients from GCC countries, the EU, USA, UK, Canada, and most Asian countries receive visa-on-arrival or visa-free entry to the UAE for up to 30–90 days. Patients from other nationalities can apply for a UAE Medical Treatment Visa through GAF Healthcare's partner facilitation service. Our Dubai and Abu Dhabi coordinators liaise directly with DHA (Dubai Health Authority) and DOH (Abu Dhabi Department of Health) registered hospitals to ensure insurance pre-authorization or self-pay billing packages are arranged before arrival.

AIRPORT & GROUND TRANSPORT: Dedicated wheelchair-accessible vehicle transfers are arranged for all arrival and departure flights. During multi-week stays, GAF Healthcare provides scheduled transport between accommodation and the hospital for all EMU monitoring sessions, outpatient appointments, and diagnostic scans — eliminating the need for patients or attendants to navigate unfamiliar transit systems.

ACCOMMODATION FOR PATIENT & ATTENDANTS: GAF Healthcare has negotiated rates at partner serviced apartments and hotels within a 5–15 minute radius of all partner epilepsy centers. Options range from budget-comfortable to premium serviced residences. Accommodations are selected based on proximity to the hospital, accessibility (elevator, ground-floor options for post-operative patients), and kitchen facilities for dietary needs. Our team checks in with attendants weekly to resolve any accommodation issues.

DEDICATED MULTILINGUAL COORDINATORS: Each patient is assigned a personal GAF Healthcare case coordinator fluent in English plus the patient's native language (Arabic, Russian, French, Hindi, Swahili, and others available). Coordinators attend key clinical consultations to facilitate accurate medical communication, assist with consent documentation comprehension, and act as the bridge between patient and clinical team throughout the stay.

TELEMEDICINE & POST-DEPARTURE FOLLOW-UP: GAF Healthcare's digital platform facilitates structured post-operative telemedicine consultations at 1 month, 3 months, 6 months, and 12 months post-surgery. All imaging and clinical reports are digitized and stored in a patient portal accessible to both the treating team in India/UAE and the patient's home-country neurologist, enabling coordinated continuity of care across borders.

Patients Also Explore

Other treatments commonly sought by patients considering Epilepsy Surgery.

Total Knee Replacement

Orthopedics

Total Hip Replacement

Orthopedics

A guide for parents bringing a child to India for brain or spine surgery — the common conditions treated, what care for children involves, realistic costs, how the family travels together, and how to choose the right centre and surgeon for a child's specific diagnosis.

Read Guide